{"schema_version":"secwatch.filing_event.v1","accession":"0001294133-26-000032","form_type":"8-K","ticker":"INGN","cik":"0001294133","company_name":"Inogen Inc","filed_at":"2026-08-06T20:10:33+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:14:04.416035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inogen Q2 revenue $95.1M (+3% YoY); raises FY adjusted EBITDA guidance to ~$4.0M","bullets":["Q2 revenue $95.1M (+3% YoY); international revenue $41.3M (+14.8% YoY).","GAAP net loss $3.9M vs $4.2M loss prior year; adjusted EBITDA positive $2.4M vs $2.1M.","Raised FY 2026 adjusted EBITDA guidance to ~$4.0M (up 48% from 2025); revenue guidance $355M-$361M.","Cash $106.8M, no debt; repurchased 1.15M shares for $7.5M in H1 2026.","Launched Rove 6 in Canada; completed Simeox H study enrollment in China; added Andy Reding as COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001294133-26-000032","json":"https://secwatch.observer/filing/0001294133-26-000032.json","markdown":"https://secwatch.observer/filing/0001294133-26-000032.md","text":"https://secwatch.observer/filing/0001294133-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1294133/000129413326000032/0001294133-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1294133/000129413326000032/ingn-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:14:04.416035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}